D. Boral Capital analyst Jason Kolbert downgraded Can-Fite BioPharma (CANF) to Hold from Buy with no price target after the company’s board approved a reverse split of its ordinary shares alongside a corresponding change in the American Depository Share ratio. The firm is lowering its rating ahead of the actual split, consistent with its policy, the analyst noted.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite BioPharma Sets 1-for-3,000 Reverse Share Split and ADS Ratio Change Effective Early January 2026
- Can-Fite BioPharma announces 1-for-3,000 reverse split, ratio change
- Can-Fite BioPharma Updates on Clinical Trials and Financials
- Can-Fite BioPharma provides clinical, financial update
- Can-Fite BioPharma to participate in BioFIT 2025